Total visits last 3 months
| Last Month Change | 31.01% | 3.92% |
| Avg Visit Duration | 00:00:25 | 00:00:46 |
| Pages per Visit | 1.41 | 1.59 |
| Bounce Rate | 70.68% | 66.12% |
| Compare any site with a free trial | ||
nucala.com VS. 
dupixenthcp.com
nucala.com
NUCALA (mepolizumab) is now approved for a new indication.
Global Rank
#836,904
dupixenthcp.com
dupixent® (dupilumab) is a dual inhibitor of il-4 and il-13 signaling and is approved for 6 indications. the mechanism of dupilumab action has not been definitively established. serious adverse reactions may occur. please see important safety information and full prescribing information on website.
Global Rank
#448,697
nucala.com vs. dupixenthcp.com Ranking Comparison
Compare nucala.com global ranking trend in the past 3 months vs. dupixenthcp.com, or dive deeper into nucala.com ranking in its category or country measured against dupixenthcp.com
Category Rank Last Month
dupixenthcp.com
#206nucala.com
#379
Traffic and Engagement
dupixenthcp.com had more total visits compared to nucala.com in March 2026.
Traffic share by country: nucala.com vs. dupixenthcp.com
nucala.com vs dupixenthcp.com country based traffic analysis shows dupixenthcp.com gets the most traffic from United States, while dupixenthcp.com gets a smaller share
Top Countries
nucala.com
16.45%
dupixenthcp.com
83.55%
United States